AMGEN INC
DEFA14A, 1995-04-26
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: UNITED STATES FILTER CORP, S-3/A, 1995-04-26
Next: INVESTORS QUALITY TAX EXEMPT TRUST SERIES 7, 485BPOS, 1995-04-26









                                 SCHEDULE 14A INFORMATION

               Proxy Statement Pursuant to Section 14(a) of the Securities
                          Exchange Act of 1934 (Amendment No.  )

          Filed by the Registrant  [X]

          Filed by a Party other than the Registrant [_]

          Check the appropriate box:

          [_]  Preliminary Proxy Statement   [_]  Confidential, for Use of the
                                             Commission Only (as permitted by
                                             Rule 14a-6(e)(2))

          [_]  Definitive Proxy Statement

          [X]  Definitive Additional Materials

          [_]  Soliciting Material Pursuant to Section 240.14a-11(c) or Section
          240.14a-12

                                        AMGEN INC
          ----------------------------------------------------------------------
                     (Name of Registrant as Specified In Its Charter)

          ----------------------------------------------------------------------
               (Name of Person(s) Filing Proxy Statement, if other than the
                                       Registrant)


          Payment of Filing Fee (Check the appropriate box):

          [X]  $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1),
          14a-6(i)(2) or Item 22(a)(2) of Schedule 14A.

          [_]  $500 per each party to the controversy pursuant to Exchange Act
          Rule 14a-6(i)(3).

          [_]  Fee computed on table below per Exchange Act Rules 14a-6(i)(4)
          and 0-11.

               (1)  Title of each class of securities to which transaction
          applies:

               -----------------------------------------------------------------

               (2)  Aggregate number of securities to which transaction applies:

               -----------------------------------------------------------------

               (3)  Per unit price or other underlying value of transaction
          computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on
          which the filing fee is calculated and state how it was determined):

               -----------------------------------------------------------------

               (4)  Proposed maximum aggregate value of transaction:

               -----------------------------------------------------------------
          <PAGE>

               (5)  Total fee paid:

               -----------------------------------------------------------------

          [_]  Fee paid previously with preliminary materials.

          [_]  Check box if any part of the fee is offset as provided by
          Exchange Act Rule 0-11(a)(2) and identify the filing for which the
          offsetting fee was paid previously.  Identify the previous filing by
          registration statement number, or the Form or Schedule and the date of
          its filing.

               (1)  Amount Previously Paid:

               -----------------------------------------------------------------

               (2)  Form, Schedule or Registration Statement No.:

               -----------------------------------------------------------------

               (3)  Filing Party:

               -----------------------------------------------------------------

               (4)  Date Filed:

               -----------------------------------------------------------------

          Notes:


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission